ES2689696T3 - Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 - Google Patents
Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 Download PDFInfo
- Publication number
- ES2689696T3 ES2689696T3 ES16169874.1T ES16169874T ES2689696T3 ES 2689696 T3 ES2689696 T3 ES 2689696T3 ES 16169874 T ES16169874 T ES 16169874T ES 2689696 T3 ES2689696 T3 ES 2689696T3
- Authority
- ES
- Spain
- Prior art keywords
- lipid
- present
- retinoid
- chain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004492 retinoid derivatives Chemical class 0.000 title abstract 4
- 239000002502 liposome Substances 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 6
- 230000000692 anti-sense effect Effects 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494832P | 2011-06-08 | 2011-06-08 | |
| US201161494832P | 2011-06-08 | ||
| US201161497447P | 2011-06-15 | 2011-06-15 | |
| US201161497447P | 2011-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2689696T3 true ES2689696T3 (es) | 2018-11-15 |
Family
ID=46395700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16169874.1T Active ES2689696T3 (es) | 2011-06-08 | 2012-06-08 | Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 |
| ES12730301.4T Active ES2586593T3 (es) | 2011-06-08 | 2012-06-08 | Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12730301.4T Active ES2586593T3 (es) | 2011-06-08 | 2012-06-08 | Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8664376B2 (enExample) |
| EP (2) | EP2717921B1 (enExample) |
| JP (1) | JP5873168B2 (enExample) |
| KR (1) | KR102002771B1 (enExample) |
| CN (1) | CN103781909B (enExample) |
| AU (1) | AU2012267472B2 (enExample) |
| CA (1) | CA2836925C (enExample) |
| CY (2) | CY1117683T1 (enExample) |
| DK (2) | DK2717921T3 (enExample) |
| ES (2) | ES2689696T3 (enExample) |
| HR (1) | HRP20181440T8 (enExample) |
| HU (1) | HUE039379T2 (enExample) |
| LT (1) | LT3075855T (enExample) |
| PL (2) | PL2717921T3 (enExample) |
| PT (2) | PT2717921T (enExample) |
| RS (1) | RS57824B1 (enExample) |
| RU (1) | RU2628694C2 (enExample) |
| SI (1) | SI3075855T1 (enExample) |
| SM (1) | SMT201800584T1 (enExample) |
| TW (1) | TWI658830B (enExample) |
| WO (1) | WO2012170957A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| US20160038593A1 (en) * | 2004-12-22 | 2016-02-11 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
| WO2011072082A2 (en) | 2009-12-09 | 2011-06-16 | Nitto Denko Corporation | Modulation of hsp47 expression |
| JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| US10196637B2 (en) * | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| EP2998289B1 (en) * | 2011-06-08 | 2019-08-07 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing sirna activity |
| US9011903B2 (en) | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US20140323550A1 (en) * | 2011-11-18 | 2014-10-30 | Nitto Denko Corporation | Intestinal fibrosis treatment agent |
| BR112014030714B1 (pt) | 2012-06-08 | 2020-12-22 | Nitto Denko Corporation | composto de lipídeo ionizável, composição, veículo de fármaco e formulação farmacêutica |
| WO2015135138A1 (en) * | 2014-03-11 | 2015-09-17 | Yi-Wen Wang | Pharmaceutical composition and method for reducing scar formation |
| CN104174034A (zh) * | 2014-08-20 | 2014-12-03 | 南京大学 | 肝星状细胞靶向的基因药物输送载体及其制备方法和应用 |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| AU2016371624B2 (en) | 2015-12-13 | 2020-08-27 | Nitto Denko Corporation | siRNA structures for high activity and reduced off target |
| CN114656378A (zh) | 2016-05-16 | 2022-06-24 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
| JP6833456B2 (ja) * | 2016-11-02 | 2021-02-24 | 日東電工株式会社 | 皮膚線維症処置剤 |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| EP3596117A4 (en) * | 2017-03-17 | 2021-01-13 | The Johns Hopkins University | TARGETED EPIGENETIC THERAPY AGAINST THE DISTAL EXPRESSION REGULATORY ELEMENT OF TGFB2 |
| WO2020181130A2 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
| TWI740533B (zh) | 2020-06-11 | 2021-09-21 | 國立中央大學 | 評估個體罹患腹膜硬化症之風險的方法、其分析器及其套組 |
| JP2023532011A (ja) * | 2020-06-24 | 2023-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 標的分子の合成方法 |
| US20230310352A1 (en) * | 2020-08-25 | 2023-10-05 | Laurent Pharmaceuticals Inc. | Novel compositions and methods for the treatment of lung fibrosis |
| JP2025504092A (ja) * | 2022-02-04 | 2025-02-06 | ニューヨーク ユニバーシティ | 心房細動の処置のためのレチノイドの使用 |
| AU2023249281A1 (en) | 2022-04-08 | 2024-10-17 | University Of North Texas Health Science Center At Fort Worth | Treatment for ocular fibrosis |
| WO2024059714A1 (en) * | 2022-09-15 | 2024-03-21 | Bristol-Myers Squibb Company | Method of treating advanced hepatic fibrosis associated with hcv infection with targeted lipid nanoparticle compositions |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US5811119A (en) | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
| PT88550A (pt) | 1987-09-21 | 1989-07-31 | Ml Tecnology Ventures Lp | Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| DK0618925T4 (da) | 1991-12-24 | 2012-07-09 | Isis Pharmaceuticals Inc | Antisense-oligonukleotider |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| DE69431669T2 (de) | 1993-09-02 | 2003-10-23 | Ribozyme Pharmaceuticals, Inc. | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| DE69415343T2 (de) | 1993-10-27 | 1999-08-26 | Ribozyme Pharmaceuticals | 2'-amido-und 2'-peptido-modifizierte oligonukleotide |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| CA2207593A1 (en) | 1994-12-13 | 1996-06-20 | John Gustofson | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| DE19640092A1 (de) | 1996-09-28 | 1998-04-16 | Beiersdorf Ag | Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind |
| DE19641672A1 (de) | 1996-10-10 | 1998-04-16 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| WO1999014226A2 (en) | 1997-09-12 | 1999-03-25 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| ATE287897T2 (de) | 1999-02-12 | 2005-02-15 | Sankyo Co | Analoga von nukleosiden und oligonukleotiden |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| DE10012151A1 (de) | 2000-03-13 | 2001-09-27 | Gsf Forschungszentrum Umwelt | Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| ATE359829T1 (de) | 2001-10-30 | 2007-05-15 | Nektar Therapeutics Al Corp | Wasserlösliche polymerkonjugate von retinoesäure |
| AUPR894201A0 (en) | 2001-11-19 | 2001-12-13 | Women's And Children's Hospital | Respiratory delivery for gene therapy and lentiviral delivery particle |
| DK1527176T4 (en) | 2002-08-05 | 2017-07-03 | Silence Therapeutics Gmbh | ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| EP1606406B2 (en) | 2003-03-21 | 2013-11-27 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
| EP1608380A2 (en) | 2003-03-31 | 2005-12-28 | Vectramed, Inc. | Polymeric drug agents for the treatment of fibrotic disorders |
| WO2005040758A2 (en) * | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| JP2009221164A (ja) * | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| DK2727583T3 (da) * | 2004-12-22 | 2021-12-20 | Nitto Denko Corp | Lægemiddelbærer og lægemiddelbærerkit til at inhibere fibrose |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| CN101448849B (zh) * | 2006-03-31 | 2013-08-21 | 阿尔尼拉姆医药品有限公司 | 抑制Eg5基因表达的组合物和方法 |
| DE202006005347U1 (de) * | 2006-04-03 | 2007-08-02 | Efbe Elektrogeräte GmbH | Infrarotleuchte |
| EP2076600A1 (en) | 2006-10-18 | 2009-07-08 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| JP2010527914A (ja) | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| US8003621B2 (en) * | 2007-09-14 | 2011-08-23 | Nitto Denko Corporation | Drug carriers |
| WO2009059450A1 (en) | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
| RU2505315C2 (ru) | 2008-07-30 | 2014-01-27 | Нитто Денко Корпорейшн | Носители лекарственных средств |
| KR20160095209A (ko) | 2008-09-12 | 2016-08-10 | 닛토덴코 가부시키가이샤 | 섬유증 질환의 조영제 |
| KR20110091796A (ko) | 2008-12-04 | 2011-08-12 | 오피케이오 큐알엔에이, 엘엘씨 | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
| WO2011072082A2 (en) * | 2009-12-09 | 2011-06-16 | Nitto Denko Corporation | Modulation of hsp47 expression |
| CA2801066C (en) * | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US9011903B2 (en) | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| TWI658830B (zh) * | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
-
2012
- 2012-06-07 TW TW101120615A patent/TWI658830B/zh active
- 2012-06-08 US US13/492,639 patent/US8664376B2/en active Active
- 2012-06-08 JP JP2014514911A patent/JP5873168B2/ja active Active
- 2012-06-08 SI SI201231369T patent/SI3075855T1/sl unknown
- 2012-06-08 PT PT127303014T patent/PT2717921T/pt unknown
- 2012-06-08 PT PT16169874T patent/PT3075855T/pt unknown
- 2012-06-08 PL PL12730301.4T patent/PL2717921T3/pl unknown
- 2012-06-08 RU RU2013158469A patent/RU2628694C2/ru active
- 2012-06-08 ES ES16169874.1T patent/ES2689696T3/es active Active
- 2012-06-08 AU AU2012267472A patent/AU2012267472B2/en not_active Ceased
- 2012-06-08 CA CA2836925A patent/CA2836925C/en active Active
- 2012-06-08 KR KR1020147000572A patent/KR102002771B1/ko active Active
- 2012-06-08 EP EP12730301.4A patent/EP2717921B1/en active Active
- 2012-06-08 RS RS20181081A patent/RS57824B1/sr unknown
- 2012-06-08 US US13/492,594 patent/US8741867B2/en active Active
- 2012-06-08 DK DK12730301.4T patent/DK2717921T3/en active
- 2012-06-08 HU HUE16169874A patent/HUE039379T2/hu unknown
- 2012-06-08 LT LTEP16169874.1T patent/LT3075855T/lt unknown
- 2012-06-08 DK DK16169874.1T patent/DK3075855T3/en active
- 2012-06-08 EP EP16169874.1A patent/EP3075855B1/en active Active
- 2012-06-08 SM SM20180584T patent/SMT201800584T1/it unknown
- 2012-06-08 PL PL16169874T patent/PL3075855T3/pl unknown
- 2012-06-08 WO PCT/US2012/041761 patent/WO2012170957A2/en not_active Ceased
- 2012-06-08 CN CN201280028300.XA patent/CN103781909B/zh active Active
- 2012-06-08 ES ES12730301.4T patent/ES2586593T3/es active Active
-
2014
- 2014-06-02 US US14/294,021 patent/US9456984B2/en active Active
-
2016
- 2016-06-17 CY CY20161100543T patent/CY1117683T1/el unknown
- 2016-09-30 US US15/283,179 patent/US10195145B2/en active Active
-
2018
- 2018-09-07 HR HRP20181440TT patent/HRP20181440T8/hr unknown
- 2018-09-11 CY CY20181100947T patent/CY1120685T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2689696T3 (es) | Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 | |
| ES2566008T3 (es) | Antagonistas de complementos y usos de los mismos | |
| ES2643576T3 (es) | Dúplex oligonucleotídicos que comprenden nucleótidos de tipo ADN y de tipo ARN y usos de los mismos | |
| CA3122393A1 (en) | Chemically-modified rnai constructs and uses thereof | |
| RU2016122168A (ru) | Антисмысловые конъюгаты, направленные на аполипопротеин b | |
| JP2015502134A5 (enExample) | ||
| WO2008094254A2 (en) | Methods and compositions for the treatment of cancer or other diseases | |
| ES2952757T3 (es) | Complejo de ácidos nucleicos | |
| RU2013107129A (ru) | Модуляция экспрессии timp1 и timp2 | |
| WO2012053741A9 (ko) | Rna 간섭을 유도하는 핵산 분자 및 그 용도 | |
| JPWO2019074110A1 (ja) | 一本鎖核酸分子およびその製造方法 | |
| JPWO2017010575A1 (ja) | β２ＧＰＩ遺伝子発現抑制核酸複合体 | |
| Kimura et al. | Intracellular build-up RNAi with single-strand circular RNAs as siRNA precursors | |
| Romanucci et al. | Hairpin oligonucleotides forming G-quadruplexes: New aptamers with anti-HIV activity | |
| JP6882735B2 (ja) | 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ | |
| JP6704196B2 (ja) | オリゴヌクレオチド | |
| HRP20100666T1 (hr) | ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE | |
| US11479769B2 (en) | Technique for treating cancer using structurally-reinforced S-TuD | |
| CN120379694A (zh) | 跨膜递送系统及其用途 | |
| US12012432B2 (en) | Nucleic acid complex, method for forming nucleic acid hybridization, pharmaceutical composition, nucleic acid probe, and complementary-strand nucleic acid complex | |
| Matsubara et al. | Synthesis of siRNAs incorporated with cationic peptides R8G7 and R8A7 and the effect of the modifications on siRNA properties | |
| Davies | A homogenous fluorescence assay of micro RNA maturation | |
| McKim | The synthesis and in vitro evaluation of short interfering RNAs that contain internal modified alkyl spacers | |
| ES2372237A1 (es) | Oligonucleótidos modificados como reguladores de la expresión génica. | |
| AR073665A1 (es) | Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv) |